The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
Abstract
Purpose: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. Methods: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results: Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81% ± 2.1% and 86% ± 9%, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36% ± 15%. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. Conclusion: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Prediction of central nervous system embryonal tumour outcome based on gene expression
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y. H., Goumnerova, L. C., Black, P. M., Lau, C., et al. (2002) · Nature · doi:10.1038/415436a · Cited by 2,371
Zeltzer, P. M., Boyett, J. M., Finlay, J. L., Albright, A. L., Rorke, L. B., Milstein, J. M., Allen, J. C., Stevens, K. R., Stanley, P., Li, H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.832 · Cited by 754
Self-citationPacker, R. J., Goldwein, J., Nicholson, H. S., Vezina, L. G., Allen, J. C., Ris, M. D., Muraszko, K., Rorke, L. B., Wara, W. M., Cohen, B. H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2127 · Cited by 617
Self-citationRis, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3470 · Cited by 533
Self-citationPacker, R. J., Sutton, L. N., Elterman, R., Lange, B., Goldwein, J., Nicholson, H. S., Mulne, L., Boyett, J., D'Angio, G., Wechsler-Jentzsch, K., et al. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.81.5.0690 · Cited by 504
Self-citationMacDonald, T. J., Brown, K. M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Y., Packer, R. J., Cogen, P., & Stephan, D. A. (2001) · Nature Genetics · doi:10.1038/ng731 · Cited by 455
Self-citationKortmann, R.-D., Kühl, J., Timmermann, B., Mittler, U., Urban, C., Budach, V., Richter, E., Willich, N., Flentje, M., Berthold, F., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00369-7 · Cited by 426
Mutism and Pseudobulbar Symptoms after Resection of Posterior Fossa Tumors in Children
Pollack, I. F., Polinko, P., Albright, L. A., Towbin, R., & Fitz, C. (1995) · Neurosurgery · doi:10.1227/00006123-199511000-00006 · Cited by 374
Taylor, R. E., Bailey, C. C., Robinson, K., Weston, C. L., Ellison, D., Ironside, J., Lucraft, H., Gilbertson, R., Tait, D. M., Walker, D. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.116 · Cited by 353
Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D'Angio, G., Siegel, K. R., & Schut, L. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.70.5.0707 · Cited by 351
Self-citationThomas, P. R. M., Deutsch, M., Kepner, J. L., Boyett, J. M., Krischer, J., Aronin, P., Albright, L., Allen, J. C., Packer, R. J., Linggood, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3004 · Cited by 305
Self-citationBailey, C. C., Gnekow, A., Wellek, S., Jones, M., Round, C., Brown, J., Phillips, A., & Neidhardt, M. K. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950250303 · Cited by 301
Gajjar, A., Hernan, R., Kocak, M., Fuller, C., Lee, Y., McKinnon, P. J., Wallace, D., Lau, C., Chintagumpala, M., Ashley, D. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.032 · Cited by 279
Self-citationExpression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.
Segal, R. A., Goumnerova, L. C., Kwon, Y. K., Stiles, C. D., & Pomeroy, S. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12867 · Cited by 241
TrkC Expression Predicts Good Clinical Outcome in Primitive Neuroectodermal Brain Tumors
Grotzer, M. A., Janss, A. J., Fung, K.-M., Biegel, J. A., Sutton, L. N., Rorke, L. B., Zhao, H., Cnaan, A., Phillips, P. C., Lee, V. M.-Y., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1027 · Cited by 223
Eberhart, C. G., Kratz, J., Wang, Y., Summers, K., Stearns, D., Cohen, K., Dang, C. V., & Burger, P. C. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.5.441 · Cited by 218
Self-citationMedulloblastoma: Clinical and biologic aspects
Packer, R. J., Cogen, P., Vezina, G., & Rorke, L. B. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.3.232 · Cited by 216
Self-citationCombined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
Lamont, J. M., McManamy, C. S., Pearson, A. D., Clifford, S. C., & Ellison, D. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0721 · Cited by 209
Medulloblastoma: Clinical and biologic aspects
Packer, R. J. (1999) · Neuro-Oncology · doi:10.1215/15228517-1-3-232 · Cited by 197
Self-citationGrotzer, M. A., Hogarty, M. D., Janss, A. J., Liu, X., Zhao, H., Eggert, A., Sutton, L. N., RORKE, L. B., Brodeur, G. M., & Phillips∥, P. C. (2001) · PubMed · Cited by 168
C-MYC expression in medulloblastoma and its prognostic value
Herms, J., Neidt, I., Lüscher, B., Sommer, A., Schürmann, P., Schröder, T., Bergmann, M., Wilken, B., Probst-Cousin, S., Hernáiz-Driever, P., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000920)89:5<395::aid-ijc1>3.0.co;2-v · Cited by 164
Oyharcabal-Bourden, V., Kalifa, C., Gentet, J. C., Frappaz, D., Edan, C., Chastagner, P. B., Sariban, E., Pagnier, A., Babin, A., Pichon, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.760 · Cited by 150
Growth Hormone Replacement Therapy in Children With Medulloblastoma: Use and Effect on Tumor Control
Packer, R. J., Boyett, J. M., Janss, A. J., Stavrou, T., Kun, L. E., Wisoff, J. H., Russo, C. L., Geyer, R. J., Phillips∥, P. C., Kieran, M. W., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.480 · Cited by 110
Self-citationPrognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma
Gilbertson, R. J., Pearson, A., Perry, R. H., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.96 · Cited by 109
Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma.
Rood, B. R., Zhang, H., Weitman, D. M., & Cogen, P. H. (2002) · PubMed · Cited by 108
Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors
MacDonald, T. J., Rood, B. R., Santi, M. R., Vézina, G., Bingaman, K. D., Cogen, P. H., & Packer, R. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-2-174 · Cited by 87
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citationRisk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Self-citationNorthcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citation
Metadata
- Authors
- Packer, R. J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P. C., Robertson, P. L., Bayer, L., LaFond, D., Donahue, B. R., Marymont, M. H., Muraszko, K., Langston, J., & Sposto, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-09-01
- Volume
- 24
- Issue
- 25
- Pages
- 4202-4208
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150794759
- Cited by
- 989
- References
- 27
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.